Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · IEX Real-Time Price · USD
46.61
-1.07 (-2.24%)
At close: Jul 19, 2024, 4:00 PM
45.68
-0.93 (-2.00%)
Pre-market: Jul 22, 2024, 6:18 AM EDT
Company Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria.
Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Agios Pharmaceuticals, Inc.
| Country | United States |
| IPO Date | Jul 24, 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 386 |
| CEO | Brian M. Goff M.B.A. |
Contact Details
Address: 88 Sidney Street Cambridge, Massachusetts 02139 United States | |
| Phone | 617-649-8600 |
| Website | agios.com |
Stock Details
| Ticker Symbol | AGIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001439222 |
| CUSIP Number | 00847X104 |
| ISIN Number | US00847X1046 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Brian M. Goff M.B.A. | Chief Executive Officer and Director |
| Cecilia Jones | Chief Financial Officer |
| James William Burns | Corporate Secretary and Chief Legal Officer |
| Dr. Sarah Gheuens M.D., Ph.D. | Chief Medical Officer and Head of Research and Development |
| Dr. Lewis Clayton Cantley Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Dr. Craig B. Thompson M.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Dr. Shin-San Su Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| T. J. Washburn Jr. | Principal Accounting Officer |
| Dr. Clive Patience Ph.D. | Chief Technical Operations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 1, 2024 | 144 | Filing |
| Jun 20, 2024 | 8-K | Current Report |
| Jun 5, 2024 | 144 | Filing |
| May 28, 2024 | 8-K | Current Report |
| May 2, 2024 | 10-Q | Quarterly Report |
| May 2, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 7, 2024 | 144 | Filing |